

General Rules for the Clinical and Pathological Study of Follow-Up Survey and Clinical Practice Guidelines: The Liver Cancer Study Group of Japan

Digestive Diseases

33, 765-770

DOI: 10.1159/000439101

Citation Report

#	ARTICLE	IF	CITATIONS
1	Treatment of lymph node recurrence in patients with hepatocellular carcinoma. <i>Surgery Today</i> , 1994, 24, 606-609.	0.7	45
2	Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2012, 47, 179-186.	2.3	14
3	Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2014, 49, 1578-1587.	2.3	37
5	Pin1 facilitates NF- κ B activation and promotes tumour progression in human hepatocellular carcinoma. <i>British Journal of Cancer</i> , 2015, 113, 1323-1331.	2.9	45
6	Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8967.	1.4	42
7	Pathological complete response after percutaneous isolated hepatic perfusion in hepatocellular carcinoma with portal vein tumor thrombosis: a case report. <i>Surgical Case Reports</i> , 2016, 2, 50.	0.2	0
8	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. <i>World Journal of Gastroenterology</i> , 2016, 22, 7289.	1.4	138
9	Clinical Features and Clinician's Diagnostic Approach to Hepatocellular Carcinoma. , 2016, , 409-423.		0
10	Macroscopic morphology for estimation of malignant potential in pancreatic neuroendocrine neoplasm. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1299-1306.	1.2	10
11	Resection of the Intraductal Growth Type of Intrahepatic Cholangiocarcinoma Following a Long-Term Observation: a Rare Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 458-461.	0.6	0
12	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. <i>British Journal of Cancer</i> , 2017, 116, 448-454.	2.9	66
13	Clinical results of proton beam therapy for hepatocellular carcinoma over 5 cm. <i>Hepatology Research</i> , 2017, 47, 1368-1374.	1.8	18
14	Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 1372-1382.	0.9	22
15	Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. <i>Hepatology International</i> , 2017, 11, 317-370.	1.9	1,537
16	Development and validation of a novel predictive scoring model for microvascular invasion in patients with hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2017, 88, 32-40.	1.2	38
17	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. <i>Digestive Diseases</i> , 2017, 35, 583-588.	0.8	7
18	Impact of Sustained Virological Response to Interferon Therapy on Recurrence of Hepatitis C Virus-Related Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 3196-3202.	0.7	16
19	Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function. <i>Liver Cancer</i> , 2017, 6, 325-336.	4.2	202

#	ARTICLE	IF	CITATIONS
20	Preoperative neutrophil-to-lymphocyte ratio as a predictor of survival after reductive surgery plus percutaneous isolated hepatic perfusion for hepatocellular carcinoma: a retrospective analysis. <i>Surgery Today</i> , 2017, 47, 385-392.	0.7	12
21	Statin use is associated with a reduced risk of hepatocellular carcinoma recurrence after initial liver resection. <i>BioScience Trends</i> , 2017, 11, 574-580.	1.1	27
22	Implication of Psoas Muscle Index on Survival for Hepatocellular Carcinoma Undergoing Radiofrequency Ablation Therapy. <i>Journal of Cancer</i> , 2017, 8, 1507-1516.	1.2	29
23	Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion. <i>World Journal of Gastroenterology</i> , 2017, 23, 7415-7424.	1.4	70
24	Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 387-396.	0.7	54
25	Liver-enriched transcription factor expression relates to chronic hepatic failure in humans. <i>Hepatology Communications</i> , 2018, 2, 582-594.	2.0	28
26	Surgical treatment strategy for hepatocellular carcinoma in patients with impaired liver function: hepatic resection or radiofrequency ablation?. <i>Hpb</i> , 2018, 20, 244-250.	0.1	9
27	Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. <i>Radiotherapy and Oncology</i> , 2018, 129, 112-122.	0.3	80
28	Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. <i>Journal of Gastroenterology</i> , 2018, 53, 281-290.	2.3	42
29	Two patterns of contrast-enhanced ultrasonography with Sonazoid® in spontaneous rupture of hepatocellular carcinoma: a report of four cases. <i>Journal of Medical Ultrasonics (2001)</i> , 2018, 45, 319-323.	0.6	4
30	A case of intrahepatic cholangiocarcinoma that was difficult to diagnose prior to surgery: A case report. <i>Oncology Letters</i> , 2018, 17, 823-830.	0.8	1
31	Perforation of the esophagus due to thermal injury after laparoscopic radiofrequency ablation for hepatocellular carcinoma: a case for caution. <i>Surgical Case Reports</i> , 2018, 4, 127.	0.2	4
32	Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 215-224.	4.2	56
33	No Muscle Depletion with High Visceral Fat as a Novel Beneficial Biomarker of Sorafenib for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2018, 7, 359-371.	4.2	29
34	Prognostic significance of CD68, CD163 and Folate receptor ^β positive macrophages in hepatocellular carcinoma. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4465-4476.	0.8	49
35	EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2018, 38, 4101-4109.	0.5	19
36	Combined antitumor effects of 1,25-dihydroxy vitamin _D 3 and Notch inhibitor in liver cancer. <i>Oncology Reports</i> , 2018, 40, 1515-1524.	1.2	7
37	Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 1118-1130.	1.8	13

#	ARTICLE	IF	CITATIONS
38	Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis. <i>Liver Cancer</i> , 2019, 8, 121-129.	4.2	159
39	Microsatellite Analysis of Recurrent Lesions Confirms Merit of Anatomical Liver Resection for Hepatocellular Carcinoma. <i>Anticancer Research</i> , 2019, 39, 4315-4324.	0.5	2
40	Management of patients with hepatocellular carcinoma and portal vein tumour thrombosis: comparing east and west. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 721-730.	3.7	105
41	Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 822.	1.1	12
42	Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan. <i>Internal Medicine</i> , 2019, 58, 3069-3075.	0.3	4
43	Outcome of a second hepatectomy in octogenarians with hepatocellular carcinoma recurrence: single centre's experience. <i>ANZ Journal of Surgery</i> , 2019, 89, 1270-1274.	0.3	1
44	Serum anti-EIF3A autoantibody as a potential diagnostic marker for hepatocellular carcinoma. <i>Scientific Reports</i> , 2019, 9, 11059.	1.6	25
45	Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection: a propensity score matching analysis. <i>Hpb</i> , 2019, 21, 1687-1696.	0.1	57
46	Clinical predictors of small solitary hepatitis B virus-related hepatocellular carcinoma microinvasion. <i>ANZ Journal of Surgery</i> , 2019, 89, E438-E442.	0.3	0
47	Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy. <i>Anticancer Research</i> , 2019, 39, 5695-5701.	0.5	30
48	Ultrasonography surveillance improves prognosis of patients with hepatocellular carcinoma. <i>Molecular and Clinical Oncology</i> , 2019, 11, 325-330.	0.4	0
49	Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. <i>Japanese Journal of Radiology</i> , 2019, 37, 781-792.	1.0	9
50	A novel therapeutic strategy for esophageal varices using endoscopic treatment combined with splenic artery embolization according to the Child-Pugh classification. <i>PLoS ONE</i> , 2019, 14, e0223153.	1.1	12
51	Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy. <i>PLoS ONE</i> , 2019, 14, e0218136.	1.1	15
52	Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions—Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 3719-3728.	1.3	131
53	Assessment of the response of hepatocellular carcinoma to interventional radiology treatments. <i>Future Oncology</i> , 2019, 15, 1791-1804.	1.1	8
54	Prediction of Prognosis of Intermediate-Stage HCC Patients: Validation of the Tumor Marker Score in a Nationwide Database in Japan. <i>Liver Cancer</i> , 2019, 8, 403-411.	4.2	28
55	Genetic variants and Expression of Cytochrome p450 Oxidoreductase Predict Postoperative Survival in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 1453-1465.	1.2	7

#	ARTICLE	IF	CITATIONS
56	The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. <i>Molecular and Clinical Oncology</i> , 2019, 10, 531-540.	0.4	4
57	Effect of tolvaptan on the prognosis of patients with hepatic ascites. <i>Hepatology Research</i> , 2019, 49, 765-777.	1.8	18
58	Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 203.	1.7	6
59	Easy surveillance of muscle volume decline in chronic liver disease patients using finger circumference (<i>yubiâ€wakk&/i>) test. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 347-354.	2.9	23
60	Hepatocellular Carcinoma: Current Imaging Modalities for Diagnosis and Prognosis. <i>Digestive Diseases and Sciences</i> , 2019, 64, 934-950.	1.1	46
61	Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients. <i>Liver Cancer</i> , 2019, 8, 312-325.	4.2	88
62	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity scoreâ€matching analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1809-1816.	1.4	17
63	Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1414-1423.	0.8	4
64	Verification of inflammationâ€based prognostic marker as a prognostic indicator in hepatocellular carcinoma. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 667-675.	1.2	19
65	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066.	0.4	8
66	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in realâ€world conditions: Multicenter analysis. <i>Cancer Medicine</i> , 2019, 8, 137-146.	1.3	112
67	Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and metaâ€analysis. <i>Journal of Surgical Oncology</i> , 2019, 119, 455-463.	0.8	17
68	Hepatitis B virus X protein related lncRNA WEE2-AS1 promotes hepatocellular carcinoma proliferation and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2019, 508, 79-86.	1.0	30
69	Efficacy and prognostic factors of transarterial embolization as initial treatment for spontaneously ruptured hepatocellular carcinoma: a single-center retrospective analysis in 57 patients. <i>Japanese Journal of Radiology</i> , 2019, 37, 255-263.	1.0	4
70	Tumor Size Drives the Prognosis After Hepatic Resection of Solitary Hepatocellular Carcinoma Without Vascular Invasion. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1040-1048.	0.9	12
71	Outcomes of Non-B Non-C Hepatocellular Carcinoma with Reference to Patients with Interferon-Induced Hepatitis C Virus Eradication. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1809-1817.	0.9	3
72	Activation of extracellular signalâ€regulated kinase is associated with hepatocellular carcinoma with aggressive phenotypes. <i>Hepatology Research</i> , 2020, 50, 353-364.	1.8	9
73	Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib. <i>Liver Cancer</i> , 2020, 9, 73-83.	4.2	37

#	ARTICLE	IF	CITATIONS
74	Resección hepática con trombectomía en el tratamiento del carcinoma hepatocelular con invasión vascular macroscópica. Cirugía Española, 2020, 98, 9-17.	0.1	4
75	SARCIF combined with a simple tool for assessment of muscle abnormalities in outpatients with chronic liver disease. Hepatology Research, 2020, 50, 502-511.	1.8	11
76	The diagnostic value of PIVKA-II, AFP, AFP-L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma. Journal of Clinical Laboratory Analysis, 2020, 34, e23158.	0.9	32
77	Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies. Liver Cancer, 2020, 9, 41-49.	4.2	28
78	Microvascular Invasion and a Size Cutoff Value of 2 cm Predict Long-Term Oncological Outcome in Multiple Hepatocellular Carcinoma: Reappraisal of the American Joint Committee on Cancer Staging System and Validation Using the Surveillance, Epidemiology, and End-Results Database. Liver Cancer, 2020, 9, 156-166.	4.2	32
79	Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival. Medicine (United States), 2020, 99, e21161.	0.4	3
80	A systematic review of the impact of portal vein pressure changes on clinical outcomes following hepatic resection. Hpb, 2020, 22, 1521-1529.	0.1	7
81	<p>The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection</p>. Cancer Management and Research, 2020, Volume 12, 12077-12086.	0.9	6
82	Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1812-1819.	1.4	28
83	High-Intensity Focused Ultrasound Ablation for Unresectable Primary and Metastatic Liver Cancer: Real-World Research in a Chinese Tertiary Center With 275 Cases. Frontiers in Oncology, 2020, 10, 519164.	1.3	30
84	Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma. International Journal of Clinical Oncology, 2020, 25, 2083-2089.	1.0	4
85	Viral elimination is essential for improving surgical outcomes of hepatitis C virus-related hepatocellular carcinoma: Multicenter retrospective analysis. Annals of Gastroenterological Surgery, 2020, 4, 710-720.	1.2	6
86	Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. Journal of International Medical Research, 2020, 48, 030006052094687.	0.4	8
87	Primary undifferentiated carcinoma with osteoclast-like giant cells in liver and rapidly developing multiple metastases after curative hepatectomy: a case report. International Cancer Conference Journal, 2020, 9, 244-248.	0.2	2
88	Diagnostic Role of Contrast-enhanced Ultrasound in the Discrimination of Malignant Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma. Anticancer Research, 2020, 40, 4351-4363.	0.5	5
89	Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. JGH Open, 2020, 4, 1135-1139.	0.7	14
90	Cholangiolocarcinoma With Multiple Recurrences Successfully Treated With Repeated Liver Resection and Radiofrequency Ablation. Anticancer Research, 2020, 40, 7147-7153.	0.5	0
91	Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue. Anticancer Research, 2020, 40, 6665-6676.	0.5	5

#	ARTICLE	IF	CITATIONS
92	Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. <i>Liver Cancer</i> , 2020, 9, 518-528.	4.2	22
93	Impact of postoperative bile leakage on long-term outcome in patients following liver resection for hepatocellular carcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2020, 27, 931-941.	1.4	9
94	Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. <i>Genes and Diseases</i> , 2020, 7, 320-327.	1.5	10
95	<p>The Value of TTPVI in Prediction of Microvascular Invasion in Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4097-4105.	0.9	10
96	PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study. <i>International Journal of Surgery</i> , 2020, 80, 84-90.	1.1	3
97	Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. <i>BJS Open</i> , 2020, 4, 241-251.	0.7	11
98	Effect of surgical margin width after R0 resection for intrahepatic cholangiocarcinoma: A nationwide survey of the Liver Cancer Study Group of Japan. <i>Surgery</i> , 2020, 167, 793-802.	1.0	36
99	Hepatic Resection With Thrombectomy in the Treatment of Hepatocellular Carcinoma Associated With Macrovascular Invasion. <i>CirugAa EspaA±ola (English Edition)</i> , 2020, 98, 9-17.	0.1	1
100	Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection. <i>European Journal of Radiology</i> , 2020, 124, 108828.	1.2	14
101	Treatment strategies and prognosis for initially unresectable ruptured hepatocellular carcinoma: a single-center experience in 94 patients. <i>Diagnostic and Interventional Radiology</i> , 2020, 26, 223-229.	0.7	8
102	Surgical Outcomes of Spontaneously Ruptured Hepatocellular Carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 941-953.	0.9	20
103	Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. <i>Hepatology Research</i> , 2021, 51, 472-481.	1.8	23
104	Sphingosine-1-phosphate Receptor-1 Promotes Vascular Invasion and EMT in Hepatocellular Carcinoma. <i>Journal of Surgical Research</i> , 2021, 259, 200-210.	0.8	15
105	Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma. <i>Annals of Gastroenterological Surgery</i> , 2021, 5, 287-295.	1.2	6
106	High-intensity focused ultrasound ablation combined with transcatheter arterial chemoembolization improves long-term efficacy and prognosis of primary liver cancer. <i>Journal of Clinical Laboratory Analysis</i> , 2021, 35, e23633.	0.9	12
107	Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma. <i>Gastroenterology Report</i> , 2021, 9, 133-138.	0.6	21
108	Enhanced patterns on intraoperative contrast-enhanced ultrasonography predict outcomes after curative liver resection in patients with hepatocellular carcinoma. <i>Surgery Today</i> , 2021, 51, 764-776.	0.7	8
109	Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. <i>Journal of Gastroenterology</i> , 2021, 56, 54-66.	2.3	7

#	ARTICLE	IF	CITATIONS
110	Fluke-Associated Cholangiocarcinoma: A Regional Epidemic. , 2021, , 265-289.		2
111	What Can Be Done to Solve the Unmet Clinical Need of Hepatocellular Carcinoma Patients following Lenvatinib Failure?. Liver Cancer, 2021, 10, 115-125.	4.2	12
112	Hsa_circ_0008537 facilitates liver carcinogenesis by upregulating MCL1 and Snail1 expression via miR-153-3p. Oncology Reports, 2021, 45, 1072-1082.	1.2	3
113	The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using sonazoid. Journal of Medical Ultrasound, 2021, 28, 59-82.	0.2	13
114	Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report. Journal of International Medical Research, 2021, 49, 030006052199440.	0.4	1
115	Usefulness and limitation of indocyanine green fluorescence for detection of peritoneal recurrence after hepatectomy for hepatocellular carcinoma: a case report. BMC Surgery, 2021, 21, 107.	0.6	4
116	Value of gadoxetic acid-enhanced MRI for microvascular invasion of small hepatocellular carcinoma: a retrospective study. BMC Medical Imaging, 2021, 21, 40.	1.4	3
117	Transcriptome sequencing-based personalized analysis of hepatocellular carcinoma patients with portal vein tumor thrombus. Journal of Gastrointestinal Oncology, 2021, 12, 795-805.	0.6	4
118	Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker. Cancer Medicine, 2021, 10, 3584-3592.	1.3	7
119	Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers, 2021, 13, 2257.	1.7	1
120	Role of modern radiotherapy in managing patients with hepatocellular carcinoma. World Journal of Gastroenterology, 2021, 27, 2434-2457.	1.4	18
121	Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open, 2021, 5, 705-711.	0.7	2
122	Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification. BMC Cancer, 2021, 21, 668.	1.1	6
123	Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma. Annals of Translational Medicine, 2021, 9, 919-919.	0.7	3
124	Simple parameters predicting extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Scientific Reports, 2021, 11, 12984.	1.6	4
125	Prognostic Impact of Vessels that Encapsulate Tumor Cluster (VETC) in Patients who Underwent Liver Transplantation for Hepatocellular Carcinoma. Annals of Surgical Oncology, 2021, 28, 8186-8195.	0.7	13
126	Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 2021, Volume 8, 587-598.	1.8	1
127	Liver transplantation: would it be the best and last chance of cure for hepatocellular carcinoma with major venous invasion?. Hepatobiliary Surgery and Nutrition, 2021, 10, 308-314.	0.7	9

#	ARTICLE	IF	CITATIONS
128	Multimodal treatment involving molecular targeted agents and onâ€ demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report. <i>Molecular and Clinical Oncology</i> , 2021, 15, 154.	0.4	3
129	Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. <i>BioMed Research International</i> , 2021, 2021, 1-13.	0.9	8
130	Fas -670 A/G polymorphism predicts prognosis of hepatocellular carcinoma after curative resection in Chinese Han population. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 21, 33-33.	0.6	0
131	Impact of modified albuminâ€ bilirubin grade on survival in patients with HCC who received lenvatinib. <i>Scientific Reports</i> , 2021, 11, 14474.	1.6	13
132	Whole tumor volumetric ADC analysis: relationships with histopathological differentiation of hepatocellular carcinoma. <i>Abdominal Radiology</i> , 2021, 46, 5180-5189.	1.0	2
133	Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease. <i>Annals of Medicine and Surgery</i> , 2021, 68, 102644.	0.5	4
134	Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study. <i>Scientific Reports</i> , 2021, 11, 16663.	1.6	30
135	Rapid fluorescence imaging of human hepatocellular carcinoma using the Î²-galactosidase-activatable fluorescence probe SPiDER-Î²Gal. <i>Scientific Reports</i> , 2021, 11, 17946.	1.6	3
136	Deceased Donor Liver Transplantation After Radioembolization for Hepatocellular Carcinoma and Portal Vein Tumoral Thrombosis: A Pilot Study. <i>Liver Transplantation</i> , 2021, 27, 1758-1766.	1.3	15
137	The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. <i>Frontiers in Oncology</i> , 2021, 11, 635731.	1.3	26
138	Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2265-2274.	1.0	0
139	A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data. <i>Frontiers in Oncology</i> , 2020, 10, 576901.	1.3	11
140	Impact of Insulin Treatment on Prognosis of non-B non-C Hepatocellular Carcinoma After Hepatectomy. <i>Anticancer Research</i> , 2021, 41, 317-326.	0.5	3
141	Laparoscopic Surgery for a Patient With Multiple Liver Metastases of Unknown Origin Concomitant With Gallbladder Tumor. <i>In Vivo</i> , 2021, 35, 2963-2968.	0.6	0
142	Association Between Renal Adverse Effects and Mortality in Patients With Hepatocellular Carcinoma Treated With Lenvatinib. <i>In Vivo</i> , 2021, 35, 1647-1653.	0.6	4
143	Medical Therapy of HCC. , 2016, , 489-512.		1
144	Subclassification of Microscopic Vascular Invasion in Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2021, 274, e1170-e1178.	2.1	20
145	EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis. <i>Liver Cancer</i> , 2020, 9, 734-743.	4.2	35

#	ARTICLE	IF	CITATIONS
146	The General Rules for the Study of Primary Liver Cancer. <i>Journal of Liver Cancer</i> , 2017, 17, 19-44.	0.3	28
147	Hepatocellular Carcinoma in Korea Between 2008 and 2011: an Analysis of Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 41-52.	0.3	15
148	Hepatocellular Carcinoma in Korea between 2012 and 2014: an Analysis of Data from the Korean Nationwide Cancer Registry. <i>Journal of Liver Cancer</i> , 2020, 20, 135-147.	0.3	15
149	Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and <i>in vitro</i> assessment via protein phosphorylation array. <i>Oncotarget</i> , 2020, 11, 2531-2542.	0.8	20
150	Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers. <i>Clinical and Molecular Hepatology</i> , 2019, 25, 223-233.	4.5	28
151	Impact of national Human Development Index on liver cancer outcomes: Transition from 2008 to 2018. <i>World Journal of Gastroenterology</i> , 2019, 25, 4749-4763.	1.4	13
152	Features of extrahepatic metastasis after radiofrequency ablation for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2020, 26, 4833-4845.	1.4	13
153	Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study. <i>Oncology Letters</i> , 2020, 19, 2205-2212.	0.8	26
154	Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma. <i>JGH Open</i> , 2021, 5, 1275-1283.	0.7	12
155	Clinical and pathological characteristics of cholangiolocellular carcinoma. <i>World Chinese Journal of Digestology</i> , 2019, 27, 1114-1117.	0.0	0
157	Comparison of different surgical interventions for hepatocellular carcinoma with bile duct tumor thrombus: a systematic review and meta-analysis. <i>Annals of Translational Medicine</i> , 2020, 8, 1567-1567.	0.7	4
158	Current Status of Hepatocellular Carcinoma Occurrence after Achieving a Sustained Virologic Response with Direct-Acting Antiviral Drug Treatment for Type C Chronic Liver Disease: A Study at Kawasaki Municipal Tama Hospital. <i>Journal of St Marianna University</i> , 2020, 11, 143-152.	0.1	0
159	Malignant Tissue Optical Properties. , 2020, , 3-106.		2
161	Role of Wnt5a in suppressing invasiveness of hepatocellular carcinoma via epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2020, 20, 268.	0.8	2
162	Prediction of early recurrence and response to adjuvant Sorafenib for hepatocellular carcinoma after resection. <i>PeerJ</i> , 2021, 9, e12554.	0.9	2
163	Potential of PALBI score as a prognostic model for hepatocellular carcinoma in alcoholic liver disease. <i>JGH Open</i> , 2022, 6, 36-43.	0.7	3
164	Role of Wnt5a in suppressing invasiveness of hepatocellular carcinoma via epithelial-mesenchymal transition. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	5
165	Clinicopathologic Features of Patients With Primary Hepatocellular Carcinoma Surviving Without Recurrence More Than 10 Years After Primary Hepatic Resection. <i>International Surgery</i> , 2021, 105, 533-542.	0.0	0

#	ARTICLE	IF	CITATIONS
166	Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period. <i>Hepatology International</i> , 2022, 16, 135-147.	1.9	1
167	The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment. <i>PLoS ONE</i> , 2022, 17, e0262675.	1.1	4
168	Clinical significance of preoperative inflammation-based score for the prognosis of patients with hepatocellular carcinoma who underwent hepatectomy. <i>Surgery Today</i> , 2022, 52, 1008-1015.	0.7	3
169	Case Report: One-Year Delay in the Effect of Conversion Surgery Therapy for Advanced Hepatocellular Carcinoma After Systemic Therapy. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 810251.	1.6	2
170	Ruptured Hepatocellular Carcinoma: Current Status of Research. <i>Frontiers in Oncology</i> , 2022, 12, 848903.	1.3	22
171	Gradually progressive cholangiolocellular carcinoma: a case report. <i>Surgical Case Reports</i> , 2021, 7, 263.	0.2	1
172	Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. <i>Anticancer Research</i> , 2022, 42, 35-44.	0.5	8
173	Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads. <i>Cancer Management and Research</i> , 2021, Volume 13, 9367-9377.	0.9	2
174	Surgery for hepatocellular carcinoma with tumor thrombosis in inferior vena cava: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 11495-11503.	0.3	0
176	Decreased ARG1 expression as an adverse prognostic phenotype in non-alcoholic non-virus-related hepatocellular carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 253-263.	1.4	1
177	Hypofractionated Radiotherapy for Palliation of Main Portal Vein Tumor Thrombosis. <i>Frontiers in Oncology</i> , 2022, 12, 882272.	1.3	0
178	Improved prognosis of hepatitis C-related hepatocellular carcinoma in the era of direct-acting antivirals. <i>Hepatology Communications</i> , 2022, 6, 2496-2512.	2.0	4
179	Favorable control of hepatocellular carcinoma with peritoneal dissemination by surgical resection using indocyanine green fluorescence imaging: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	1
180	Surgical management in hepatocellular carcinoma with portal vein tumour thrombosis: is this the end of the road or a chance to expand the criteria for resectability?. <i>Przegląd Gastroenterologiczny</i> , 0, , .	0.3	0
181	Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin-bilirubin score (ALBS grade). <i>Journal of Gastroenterology</i> , 2022, 57, 581-586.	2.3	6
182	Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection. <i>Journal of Gastroenterology</i> , 0, , .	2.3	0
183	Impairment of perioperative activities of daily living is associated with poor prognosis following hepatectomy for hepatocellular carcinoma. <i>Journal of Surgical Oncology</i> , 2022, 126, 995-1002.	0.8	6
184	The impact of the covalently closed circular DNA level on recurrence of hepatocellular carcinoma after initial hepatectomy: an analysis of patients with resolved hepatitis B virus infection. <i>Hpb</i> , 2022, 24, 1780-1788.	0.1	0

#	ARTICLE	IF	CITATIONS
185	Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve. <i>Cancer Medicine</i> , 2023, 12, 2646-2657.	1.3	9
186	Texture analysis of contrast-enhanced magnetic resonance imaging predicts microvascular invasion in hepatocellular carcinoma. <i>European Journal of Radiology</i> , 2022, 156, 110528.	1.2	6
187	Early extrahepatic recurrence as a pivotal factor for survival after hepatocellular carcinoma resection: A 15-year observational study. <i>World Journal of Gastroenterology</i> , 0, 28, 5351-5363.	1.4	4
188	Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2023, 37, 1316-1333.	1.3	6
189	Is the platelet function test effective in predicting blood loss in patients undergoing hepatic resection?. <i>Annals of Surgical Treatment and Research</i> , 2022, 103, 227.	0.4	1
190	Clinical outcomes of neoadjuvant chemotherapy for resectable colorectal liver metastasis with intermediate risk of postoperative recurrence: A multi-institutional retrospective study. <i>Annals of Gastroenterological Surgery</i> , 2023, 7, 479-490.	1.2	3
191	Disability in perioperative activities of daily living is associated with worse survival outcomes following hepatic resection in patients with intrahepatic cholangiocarcinoma. <i>Hepatology Research</i> , 2023, 53, 135-144.	1.8	2
192	Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma. <i>Internal Medicine</i> , 2022, 61, 3157-3164.	0.3	1
193	Serum BRD2 autoantibody in hepatocellular carcinoma and its detection using mimotope peptide-conjugated BSA. <i>International Journal of Oncology</i> , 2022, 61, .	1.4	0
194	Liver transplantation and portal vein tumour thrombus: futile enterprise?. <i>Current Opinion in Organ Transplantation</i> , 2022, 27, 312-319.	0.8	1
195	Vater Papilla-preserving Strategy for Advanced Hepatocellular Carcinoma With Excessive Bile Duct Tumor Thrombus. <i>Anticancer Research</i> , 2022, 42, 5663-5670.	0.5	1
196	Comparison of Surgical Resection and Percutaneous Ultrasonographic Guided Radiofrequency Ablation for Initial Recurrence of Hepatocellular Carcinoma in Early Stage following Curative Treatment. <i>Cancers</i> , 2022, 14, 5524.	1.7	3
197	Towards refining the utility of dual (18F-FDG / 18F-Choline) PET/CT for the management of hepatocellular carcinoma: a tertiary center study. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	0.4	0
198	Emergency versus delayed hepatectomy following transarterial embolization in spontaneously ruptured hepatocellular carcinoma survivors: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2022, 20, .	0.8	3
199	Selecting the Best Approach for the Treatment of Multiple Non-Metastatic Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 5997.	1.7	7
200	Efficacy and Safety of Combined Ethanol-Lipiodol Mixture and Drug-Eluting Bead TACE for Large HCC. <i>Journal of Hepatocellular Carcinoma</i> , 0, Volume 10, 81-90.	1.8	1
201	A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension. <i>Journal of Gastroenterology</i> , 0, , .	2.3	1
202	The influence of resection margin width in patients with intrahepatic cholangiocarcinoma: a meta-analysis. <i>World Journal of Surgical Oncology</i> , 2023, 21, .	0.8	5

#	ARTICLE	IF	CITATIONS
203	The Role of Branched-Chain Amino Acid Supplementation in Combination with Locoregional Treatments for Hepatocellular Carcinoma: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2023, 15, 926.	1.7	5
204	A case of successful surgical treatment for peritoneal seeding of hepatocellular carcinoma after radiotherapy and atezolizumab plus bevacizumab combination treatment. <i>Journal of Liver Cancer</i> , 2023, 23, 206-212.	0.3	1
205	Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial. <i>Hepatology Research</i> , 2023, 53, 649-660.	1.8	4
206	Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy. <i>Cancers</i> , 2023, 15, 1834.	1.7	2
207	Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 242-251.	4.5	4